Nope, but lets reflect on where we are at:
- All products are now before the FDA which is a plus, rather than just one product like was the case with the Europeans.
- Mgt have learned and not trying to predict when the FDA will make up their mind.
- If FDA comes through then massive tick on proof of concept and tripple digit market cap is pretty much the odds on direction we can hope for.
- It's a huge positive to have J&J in the mix, if the study turns out to be positve then BOOM - there is an uplift on the perception J&J may formalise a stragetic alliace into a JV of some sorts, not to mention the leveraged distribution network.
- European marketing is making good progress: 4 out of 10 viable markets to get distribution centres signed up for, and revenues are growing.
- Mgt are ramping up marketing, building the business, growing the client base and broadening the scope for revenues.
- Investor relations has improved too, which is a massive positive tick for transparency.
Overall, management have lifted their game and moving the business forward to where it should be and, in due time, the market will appreciate this and we'll get our long overdue re-rate.
OCC Price at posting:
30.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)